Skip to main content

Table 2 Associations of genetic proxies for antihypertensive drugs with UACR in CKDGen

From: Using Mendelian randomization study to assess the renal effects of antihypertensive drugs

Class

#SNPs

Beta

95% CI

p

ACE inhibitors

1

0.07

−0.37, 0.51

0.76

ARBs

1

−0.06

−0.70, 0.58

0.86

CCBs

9

−0.15

−0.28, − 0.02

0.03

Alpha-adrenoceptor blockers

6

−0.10

−0.25, 0.05

0.17

Adrenergic neuron blockers

3

−0.12

−0.41, 0.16

0.39

Beta-adrenoceptor blockers

7

−0.04

−0.17, 0.10

0.58

Centrally acting antihypertensives

4

−0.24

−0.49, 0.01

0.06

Loop diuretics

2

0.17

−0.17, 0.52

0.33

PSDs and aldosterone antagonists

4

−0.14

−0.56, 0.29

0.53

Renin inhibitors

1

−0.27

−0.80, 0.27

0.33

Thiazides and related diuretics

4

−0.10

−0.52, 0.32

0.63

Vasodilator antihypertensives

8

−0.07

−0.23, 0.09

0.39

  1. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; PSD, potassium-sparing diuretic; UACR, urine albumin-to-creatinine ratio